IL2 and inflammatory breast carcinoma: Adding new and potent immunomodulators, such as CPMV, cavrotolimod, CFA, and IL-2/IL-12, and other safe, affordable, and potentially effective therapies against this extremely aggressive and metastatic disease provides a pathway to significantly improve patients’ outcomes and eliminate IBC as a therapeutic orphan disease.